Louis Edward Tamayo, the Chief Financial Officer of $LXEO, sold 4,641 shares of the company on 07-01-2026 for an estimated $20,838. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.6% of their shares of this class of stock. Following this trade, they now own 97,024 shares of this class of $LXEO stock.
$LXEO Insider Trading Activity
$LXEO insiders have traded $LXEO stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $LXEO stock by insiders over the last 6 months:
- RICHARD NOLAN TOWNSEND (Chief Executive Officer) has made 0 purchases and 4 sales selling 94,462 shares for an estimated $511,230.
- NARINDER PAL BHALLA (Chief Medical Officer) sold 22,306 shares for an estimated $98,592
- JOSE MANUEL OTERO (Chief Operating Officer) has made 0 purchases and 3 sales selling 8,984 shares for an estimated $46,803.
- LOUIS EDWARD TAMAYO (Chief Financial Officer) sold 4,641 shares for an estimated $20,838
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LXEO Hedge Fund Activity
We have seen 82 institutional investors add shares of $LXEO stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AFFINITY ASSET ADVISORS, LLC added 1,850,211 shares (+57.8%) to their portfolio in Q1 2026, for an estimated $10,620,211
- VANGUARD GROUP INC added 1,668,020 shares (+74.9%) to their portfolio in Q4 2025, for an estimated $16,563,438
- ORBIMED ADVISORS LLC added 1,477,450 shares (+69.5%) to their portfolio in Q1 2026, for an estimated $8,480,563
- AVORO CAPITAL ADVISORS LLC removed 1,425,000 shares (-43.2%) from their portfolio in Q1 2026, for an estimated $8,179,500
- PARADIGM BIOCAPITAL ADVISORS LP added 1,420,936 shares (+29.8%) to their portfolio in Q1 2026, for an estimated $8,156,172
- GOLDMAN SACHS GROUP INC added 1,168,030 shares (+149.4%) to their portfolio in Q1 2026, for an estimated $6,704,492
- D1 CAPITAL PARTNERS L.P. removed 978,652 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,718,014
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$LXEO Analyst Ratings
Wall Street analysts have issued reports on $LXEO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/13/2026
To track analyst ratings and price targets for $LXEO, check out Quiver Quantitative's $LXEO forecast page.
$LXEO Price Targets
Multiple analysts have issued price targets for $LXEO recently. We have seen 3 analysts offer price targets for $LXEO in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $9.0 on 06/25/2026
- Geulah Livshits from Chardan Capital set a target price of $17.0 on 05/11/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $10.0 on 01/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
